TCS launches AgentHub to help pharma companies scale AI across drug development and R&D; shares trade lower

TCS ADD™ AgentHub is a role-based, enterprise-ready, and trusted AI platform that will help the pharma industry scale AI with confidence across the Research and Development (R&D) value chain in highly regulated environments, TCS said. This new agentic AI workforce will also transform clinical trials and pharmacovigilance services while maintaining regulatory and audit requirements.

TCS said pharmaceutical companies operate in highly regulated environments and face challenges related to trust, governance and scalability while applying AI across functions. The IT services firm added that growing data volumes, fragmented systems and increasing regulatory requirements across clinical development and pharmacovigilance were adding complexity to the R&D value chain.

The AgentHub provides a structured framework to mitigate these challenges. Within the framework, AI agents can operate with clear roles, defined oversight, and built‑in auditability.

The firm explained that pharma companies can custom-build their AI agent hub and deploy them across clinical workflows. The platform allows rapid and streamlined integration with minimal effort, accelerating adoption while maintaining regulatory compliance.

The platform also supports workflows across clinical development and pharmacovigilance through AI workers that handle tasks such as ICSR intake, data entry, coding, review and literature analysis, as well as study design, protocol digitisation, clinical data review, SDTM (Study Data Tabulation Model) transformation and medical monitoring assistance.

Commenting on the development, TCS President, Lifesciences and Healthcare Debashis Ghosh said that TCS ADD AgentHub enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment.

“TCS’ strategy is to move towards autonomous enterprise functions where AI agentic workforce operates alongside humans driving innovation in drug development and improving patient safety,” Ghosh added.

TCS share price trends

At 11:52 AM, TCS shares were trading at ₹2,324.5 apiece on NSE, falling 1.55%. The stock has slipped 2% to touch an intraday low of ₹2,311 per share on Monday as IT stocks trade lower.

Over a month’s time, the stock has gained 2.5%, while it has tumbled 14% in the last six months. From the beginning of the year, TCS shares have tanked 28%.

Shares of the firm had hit a 52-week high of ₹3,350 on February 3, 2026, and a 52-week low of ₹1,976.80 on July 1, 2026.

According to NSE data, as of August 17, 2026, TCS has a total market capitalisation of ₹8.42 lakh crore.